Tag - DBVT

Developments

DBV Technologies gets FDA complete response letter for Viaskin Peanut

The FDA issued DBV Technologies (NASDAQ:DBVT) a complete response letter (CRL) regarding the company’s BLA for Viaskin Peanut, and epicutaneous patch to treat peanut allergies in children. The FDA identified concerns...

August 5, 2020

Markets

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $6 from $18 after the FDA raised questions about DBV’s Viaskin Peanut’s efficacy, including the impact of patch...

March 17, 2020

Tag - DBVT

DBV Technologies gets FDA complete response letter for Viaskin Peanut

Stifel cuts DBV Technologies to hold; PT to $6 from $18

General

More